U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07238985) titled 'Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease' on Nov. 15.
Brief Summary: Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries (1). NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. NAFLD is characterized by excessive hepatic fat accumulation without other recognized causes of increased fat content (e.g., alcohol, virus, drugs, and autoimmunity). According to the Clinical Practice Guidelines of the European Association for the Study of the Liver, the diagnosis of NAFLD req...